HIV Therapies: Maturation Inhibitor R&D Bears Fruit At ViiV Healthcare
Combination Study With nRTIs Starts
Executive Summary
A potent HIV maturation inhibitor has entered Phase IIb at ViiV Healthcare, in combination studies with other antiretrovirals, as the latest potential first-in-class agent to move along the company’s pipeline.